Inhibitor of nuclear factor kappa B kinase regulatory subunit gamma (IKBKG (NEMO))

Inhibitor of nuclear factor kappa B kinase regulatory subunit gamma (IKBKG), also known as NEMO, is a regulatory scaffold protein essential for the canonical activation of the NF-kappaB pathway[2][3]. It forms part of the IKK complex together with catalytic subunits IKKα and IKKβ, facilitating the phosphorylation and proteasomal degradation of I-kappa-B inhibitors and allowing nuclear translocation of NF-kappaB transcription factors. IKBKG recognizes and binds both K63- and linear polyubiquitin chains, a critical step in immune receptor and cytokine signaling. Mutations in IKBKG cause several genetic diseases, including incontinentia pigmenti and ectodermal dysplasia with immunodeficiency, by disrupting immune, inflammatory, and developmental signaling. IKBKG is a validated but challenging therapeutic target; systemic inhibition is linked to severe safety concerns due to its central physiological roles[2][3][1].

Other names

NEMONF-kappa-B essential modulatorIKK-gammaIKKGIKKAP1FIP3Fip3pI-kappa-B kinase subunit gammaInhibitor of kappa light polypeptide gene enhancer in B-cells kinase gammaIkB kinase-associated protein 1ZC2HC914.7K (adenovirus E3 protein) interacting protein 3AMCBX1EDAID1IMD33IPIP1IP2IPD2SAIDXIncontinentia pigmenti

Inhibition of NEMO–IKK complex formation disrupts NF-kappaB signaling by preventing phosphorylation and subsequent degradation of I-kappa-B proteins, resulting in blocked nuclear translocation of NF-kappaB transcription factors[2][3]. Peptides or molecules that bind NEMO and disrupt its interaction with IKKα and IKKβ can suppress canonical NF-kappaB signaling[3].